#1 Clinical Trials Search in Europe

Fluasterone

Fluasterone, a novel buccal tablet medication, is currently being studied in clinical trials for its potential to manage high blood sugar levels in adults with Cushing’s syndrome. This rare hormonal disorder, characterized by excessive cortisol production, often leads to complications such as impaired glucose tolerance and diabetes. The ongoing research aims to evaluate the efficacy and safety of Fluasterone in controlling hyperglycemia associated with Cushing’s syndrome, offering hope for improved treatment options for affected individuals.

Table of Contents

What is Fluasterone?

Fluasterone is a new medication being studied for its potential to help people with Cushing’s syndrome, especially those who have high blood sugar levels as a result of this condition. It comes in the form of a buccal tablet, which means it’s designed to be placed between your gum and cheek where it slowly dissolves.[1]

What is Cushing’s Syndrome?

Cushing’s syndrome is a hormonal disorder caused by high levels of a hormone called cortisol in your body for a long time. This can lead to various health problems, including weight gain, high blood pressure, and high blood sugar (which can lead to diabetes).[1]

How Fluasterone May Help

Researchers are studying Fluasterone to see if it can help control high blood sugar (also called hyperglycemia) in adults with Cushing’s syndrome. They think it might be able to improve how the body handles sugar, which could be very helpful for people with this condition who often struggle with diabetes or pre-diabetes.[1]

Ongoing Research

A clinical trial is currently underway to test Fluasterone. This study is called a “Double-Blind, Placebo-Controlled, Crossover Pilot Study”. Here’s what this means:

  • Double-Blind: Neither the patients nor the doctors know who is getting the real medicine and who is getting a placebo (a dummy pill with no active ingredient).
  • Placebo-Controlled: Some patients will receive Fluasterone, while others will receive a placebo. This helps researchers determine if Fluasterone is truly effective.
  • Crossover: Patients will switch between Fluasterone and placebo during different parts of the study. This allows each patient to serve as their own control, which can make the results more reliable.
  • Pilot Study: This is an early-stage study to gather initial data on how well Fluasterone works and how safe it is.[1]

Potential Benefits

The researchers are looking at several potential benefits of Fluasterone:

  1. Blood Sugar Control: The main goal is to see if Fluasterone can help lower blood sugar levels in people with Cushing’s syndrome.
  2. Lipid Profile Improvement: They’re also checking if it can help improve cholesterol and other fat levels in the blood.
  3. Body Composition Changes: The study will look at whether Fluasterone affects body fat distribution, which is often altered in Cushing’s syndrome.
  4. Liver Health: Some patients with Cushing’s syndrome develop fatty liver disease. The study will check if Fluasterone has any effect on this.[1]

Who Might Be Eligible for Fluasterone Treatment?

The study is looking for adults aged 18-75 who have been diagnosed with Cushing’s syndrome and also have either impaired glucose tolerance (pre-diabetes) or type 2 diabetes. However, there are many specific criteria for who can and can’t participate in the study. For example:

  • Participants must have certain test results that confirm Cushing’s syndrome.
  • Their diabetes must not be too severe (HbA1c less than 9%).
  • They can’t have certain other health conditions or be taking certain medications.[1]

Safety Considerations

As with any new medication, safety is a top priority. The study will carefully monitor participants for any side effects or safety concerns. Some things they’ll be watching for include:

  • How well patients tolerate the medication
  • Any changes in heart rhythm
  • Liver and kidney function
  • Potassium levels in the blood

It’s important to note that Fluasterone is still in the research phase. It’s not yet approved for general use, and we don’t know all of its potential side effects or long-term impacts. That’s why careful studies like this one are so important.[1]

Aspect Details
Study Type Phase II clinical trial, double-blind, placebo-controlled, crossover pilot study
Medication Fluasterone buccal tablet (25 mg, 50 mg, 75 mg doses)
Target Condition Hyperglycemia in adults with endogenous Cushing’s syndrome
Primary Objective Determine the effect of Fluasterone on hyperglycemia associated with Cushing’s syndrome
Secondary Objectives Assess safety, tolerability, effects on lipid profile, body habitus, and nonalcoholic fatty liver disease
Study Duration Two 12-week treatment periods with a 21-day washout period in between
Key Inclusion Criteria Adults 18-75 years, evaluated for Cushing’s syndrome, diagnosed with impaired glucose tolerance or type 2 diabetes
Primary Endpoint Change in area under the curve for glucose (AUCglucose) based on 2-hour oGTT at week 12 vs baseline

FAQ

  • What is Fluasterone and how is it being studied? Fluasterone is a new medication in the form of a buccal tablet (a tablet that dissolves in the mouth) that is being studied for its potential to control high blood sugar in adults with Cushing's syndrome. It is being tested in a clinical trial to see how well it works and how safe it is for patients.
  • Who can participate in this clinical trial? The trial is open to adults aged 18 to 75 who have been evaluated for Cushing's syndrome in the past 12 months and have either impaired glucose tolerance or type 2 diabetes. Participants must meet specific criteria related to their condition and overall health to be eligible.
  • How long does the clinical trial last? The trial consists of two 12-week treatment periods separated by a 21-day washout period. In total, participants will be involved in the study for approximately 27 weeks, including the washout period.
  • What are the different doses of Fluasterone being tested? The trial is testing three different doses of Fluasterone: 25 mg, 50 mg, and 75 mg. Some participants will receive a placebo (a tablet with no active medication) for comparison.
  • What are the main goals of this clinical trial? The primary goal is to determine how Fluasterone affects blood sugar levels in patients with Cushing's syndrome. Secondary goals include assessing its safety, evaluating its effects on lipid profiles (fats in the blood), body composition, and liver health in these patients.

Ongoing Clinical Trials on Fluasterone

  • Study on Fluasterone for Managing High Blood Sugar in Adults with Cushing’s Syndrome

    Recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Greece

Glossary

  • Cushing's syndrome: A hormonal disorder caused by prolonged exposure to high levels of cortisol, a stress hormone produced by the adrenal glands. It can lead to various health problems, including high blood sugar, weight gain, and changes in body composition.
  • Hyperglycemia: A condition characterized by high blood sugar levels, which is common in people with Cushing's syndrome and can lead to diabetes if left untreated.
  • Buccal tablet: A type of medication that is placed between the gum and cheek to dissolve and be absorbed through the lining of the mouth.
  • Placebo: A substance that has no active medical effects, used in clinical trials to compare the effectiveness of a new drug against a non-active treatment.
  • Impaired glucose tolerance: A pre-diabetic state where blood sugar levels are higher than normal but not high enough to be diagnosed as diabetes.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • Oral Glucose Tolerance Test (oGTT): A test used to diagnose diabetes and impaired glucose tolerance by measuring how well the body processes glucose.
  • DEXA scanning: A type of X-ray that measures bone density and body composition, used in the study to evaluate changes in body habitus.
  • Lipid profile: A blood test that measures different types of fats (lipids) in the blood, including cholesterol and triglycerides.
  • Washout period: A period during a clinical trial when participants stop taking the study medication to allow its effects to wear off before starting the next phase of treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-fluasterone-for-managing-high-blood-sugar-in-adults-with-cushings-syndrome/